Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 26, 2021

Initiator Pharma obtains approval to begin trial for pain-reducing effects

The Phase I study will use IP2015 in healthy male subjects challenged with pain-inducing ingredient (capsaicin).

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the local Ethics Committee have approved Initiator Pharma’s clinical trial application (CTA) for Phase I trial to evaluate pain-reducing effects.

The planned Phase I study in the new IPTN2021 clinical programme will be carried out together with MAC Clinical Research, UK.

It will use the drug substance, IP2015, in healthy male subjects challenged with pain-inducing ingredient (capsaicin).

The clinical programme is targeting an orphan drug indication being developed to treat severe neuropathic pain, trigeminal neuralgia.

It is based on the company’s IPED2015 API, which has already demonstrated safety and tolerability in clinical trials and showed efficacy for erectile dysfunction.

A monoamine reuptake inhibitor, IP2015 specially inhibits dopamine and serotonin reuptake.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

It has also been used as the active pharmaceutical ingredient in the IPED2015 programme, which is now undergoing a Phase IIb trial in 120 patients to treat organic erectile dysfunction.

Initiator Pharma CEO Claus Elsborg Olesen said: “I’m very pleased we have received the approval to start this exploratory Phase I trial for our new IPTN2021 programme targeting the orphan drug indication trigeminal neuralgia.

“The study will provide important pain-related efficacy, biomarker and safety information to support the planned clinical development of our drug substance IP2015 into relevant pain indications.

“We hope to be able to start dosing the first patients early next year. Our intention is to follow up this trial with a Phase II trial, including trigeminal neuralgia patients.”

The company expects subject enrolment and dosing to begin early next year.

In March 2020, Initiator Pharma reported favourable data from the Phase IIa study that assessed IPED2015 in severe erectile dysfunction patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU